2,141 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by RMR Wealth Builders

RMR Wealth Builders bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,141 shares of the biopharmaceutical company's stock, valued at approximately $1,358,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital International Investors boosted its stake in shares of Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after acquiring an additional 1,390,534 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after acquiring an additional 155,369 shares in the last quarter. Dodge & Cox grew its holdings in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after buying an additional 9,381 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after buying an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in Regeneron Pharmaceuticals by 7.9% in the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after buying an additional 149,124 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on REGN shares. UBS Group lowered their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a report on Thursday, June 5th. Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday, June 2nd. The Goldman Sachs Group reduced their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Finally, Royal Bank of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price for the company. in a research report on Friday, May 30th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $836.48.

Regeneron Pharmaceuticals Trading Up 1.4%

Shares of NASDAQ REGN traded up $7.40 during midday trading on Friday, hitting $529.24. The stock had a trading volume of 951,512 shares, compared to its average volume of 877,247. The company's 50-day simple moving average is $563.19 and its 200 day simple moving average is $649.98. The firm has a market cap of $57.14 billion, a P/E ratio of 13.83, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the business posted $9.55 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.